Renalytix plc
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $2.3M | $3.4M | $3.0M |
| Cost of Revenue | $2.1M | $2.7M | $2.1M |
| Gross Profit | $156.0K | $720.0K | $874.0K |
| Gross Margin | 6.8% | 21.2% | 29.4% |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | $19.8M | $28.7M | $39.5M |
| Operating Income | $-29.6M | $-42.2M | $-53.2M |
| Operating Margin | -1,293.5% | -1,240.7% | -1,790.7% |
| Interest Expense | — | — | — |
| Pretax Income | $-33.5M | $-45.6M | $-45.3M |
| Income Tax Expense | $4.0K | $2.0K | $25.0K |
| Net Income | $-33.5M | $-45.6M | $-45.3M |
| Net Margin | -1,461.6% | -1,340.2% | -1,524.4% |
| EPS (Basic) | $-0.31 | $-0.55 | $-0.62 |
| EPS (Diluted) | $-0.31 | $-0.55 | $-0.67 |
| Shares Outstanding (Basic) | 108.2M | 82.2M | 72.9M |
| Shares Outstanding (Diluted) | 108.2M | 82.2M | 73.8M |
| Dividends Per Share | — | — | — |